Study of once-daily inhaled TPIP for pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of pulmonary arterial hypertension (PAH) — not caused by other lung or heart conditions.
- You are on 1 to 3 stable PAH medications (like ambrisentan, sildenafil, or sotatercept) for at least 3 months.
- You can walk between 150 and 450 meters (about 1.5–5 football fields) in 6 minutes.
- You have had a right heart catheterization showing PAH pressures (your doctor can confirm).
- You do not have significant lung disease, left heart disease, or recent blood clots in the lungs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study provides continued access to an investigational inhaled medicine (treprostinil palmitil inhalation powder) for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD) who have already been in earlier studies of this treatment. It allows you to keep receiving the treatment under medical supervision.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This early-stage study tests how the body processes a new inhaled breathing medication (treprostinil) and whether it's safe in people with normal liver function and those with chronic liver disease. The goal is to understand if the medication works differently depending on liver health.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.